Dow Jones Newswires: Ipsen to acquire U.S.-based Epizyme for $247 million.
The primary focus of the acquisition is the lead medicine, Tazverik, which was granted FDA accelerated approval in 2020
The primary focus of the acquisition is the lead medicine, Tazverik, which was granted FDA accelerated approval in 2020